Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults
- Conditions
- Middle East Respiratory Syndrome Coronavirus
- Interventions
- Other: Normal (9%) SalineBiological: SAB-301
- Registration Number
- NCT02788188
- Brief Summary
Background:
Middle East Respiratory Syndrome (MERS) is a newly discovered contagious and sometimes fatal respiratory virus. People often get MERS through close contact with an infected person. Scientists are worried that MERS may spread and cause more infections. There are no vaccines or treatments for MERS right now. Researchers think a new therapy called SAB-301 may be able to help. Antibodies are proteins the body makes to attack viruses. SAB-301 is made of antibodies made in cows to fight MERS. The antibodies are collected from plasma, the liquid part of cow blood.
Objective:
To evaluate the safety and tolerability of SAB-301 in healthy adults.
Eligibility:
Healthy people ages 18 60 who:
Do not have chronic medical problems
Do not take any medications (exceptions are acetaminophen, ibuprofen, vitamins, seasonal allergy meds and oral contraception)
Do not have allergies to beef products
Agree to use two forms of contraception while on study (both men and women)
Design:
Participants will be screened with:
Medical history
Physical examination
Blood and urine tests
Participants will have a return visit.
They will have a physical exam and blood tests.
They will be randomly assigned to receive either SAB-301 or a placebo which is given by infusion
through an arm vein over 1 3 hours.
They will be monitored at the clinic for 6 hours after the infusion. They will have additional blood draws.
Participants will have 2-hour visits 1, 3, 7, 21, 42, and 90 days after the infusion. At each visit they will be evaluated and have blood and urine tests.
- Detailed Description
The administration of convalescent plasma or hyperimmune immunoglobulin is often used for treatment of emerging infectious diseases. However, production of large quantities of anti-pathogen human plasma and/or immunoglobulin with high affinity and avidity antibodies currently requires donations by convalescent humans, a process that can limit availability for a number of reasons. One novel alternative source is transchromosomic (Tc) cattle that produce fully human polyclonal IgG (hIgG) de novo and mount a robust antibody immune response after vaccination.
This study will evaluate the safety, tolerability, and immunogenicity of SAB-301, a fully human polyclonal anti-MERS IgG collected from transchromosomic cattle. Beginning with a low single-dose, subjects are randomized to receive either SAB-301 or a normal saline control, and evaluated on Study Days 1, 3, 7, 21, 42, and 90. The safety and tolerability is evaluated using symptoms, clinical laboratory tests, pharmacokinetics, and immunogenicity assays. Utilizing a series of stopping rules and a medical monitor, the dose will be escalated as safety and tolerability are established.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 38
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Normal (9%) Saline Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm. Cohort 1 SAB-301 Cohort 1: 1mg/kg SAB-301 in normal (9%) saline; concentration 1mg/mL (0.1%) Cohort 4 SAB-301 Cohort 4: 10mg/kg SAB-301 in normal (9%) saline; concentration 4mg/mL (0.4%) Cohort 2 SAB-301 Cohort 2: 2.5 mg/kg SAB-301 in normal (9%) saline; concentration 1mg/mL (0.1%) Cohort 5 SAB-301 Cohort 5: 20mg/kg SAB-301 in normal (9%) saline; concentration 20mg/mL (2%) Cohort 3 SAB-301 Cohort 3: 5mg/kg SAB-301 in normal (9%) saline; concentration 4mg/mL (0.4%) Cohort 6 SAB-301 Cohort 6: 50mg/kg SAB-301 in normal (9%) saline; concentration 20mg/mL (2%)
- Primary Outcome Measures
Name Time Method Number of Participants Having Adverse Events 90 days Number of participants who experienced an adverse event
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
National Institutes of Health Clinical Center
🇺🇸Bethesda, Maryland, United States